Brief: Yumanity Therapeutics To Present Anti-CD27 Agonist Preclinical Program At AACR Conference
13/10/2022 23:02
Oct 13 (Reuters) - Yumanity Therapeutics Inc YMTX.O :
* YUMANITY THERAPEUTICS INC - KINETA TO PRESENT ANTI-CD27
AGONIST
PRECLINICAL PROGRAM AT AACR CONFERENCE ON TUMOR IMMUNOLOGY AND
IMMUNOTHERAPY
Source (https://bit.ly/3SeZi09)
Further company coverage: YMTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kineta
See all newsBrief: TuHURA Biosciences And Kineta Stockholders Approve Proposed Merger And All Related Proposals
Brief: Kineta Updates KVA12123 Clinical Results From Ongoing Phase 1/2 Vista101 Study At Society For Immunotherapy Of Cancer
U.S. STOCKS ON THE MOVE-Copper miners, Palo Alto Networks, Lowe's
U.S. STOCKS ON THE MOVE-Lineage, J.B. Hunt, McDonald's
Kineta rises on resuming enrollment in early-stage cancer study